A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDS

Inclusion Criteria Concurrent Medication: Allowed: * Zidovudine (AZT). * Didanosine (ddI). Patients must have the following: * Diagnosis of AIDS as defined by the CDC. * Blood cultures positive for Mycobacterium avium complex or for acid-fast bacilli (AFB). * Provide written informed consent. Prior Medication: Allowed: * If receiving zidovudine (AZT) or ddI must be taking the medication for at least 4 weeks prior to study entry. * Required: * Antipneumocystis prophylactic therapy for at least 4 weeks prior to study entry. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Known hypersensitivity to any of the study drugs. Concurrent Medication: Excluded: * Other therapy for mycobacterial disease. Patients with the following are excluded: * Known hypersensitivity to any of the study drugs. Prior Medication: Excluded within 4 weeks: * Therapy for mycobacterial disease. * Antiretroviral drugs, other than zidovudine (AZT) or ddI. * Investigational drugs, other than ddI.